Charache S, Terrin ML, Moore RD, et al
Selectively interacts with ghrelin (GHS-R1a) receptors in research models
For retatrutide , phase 2 data published in the New England Journal of Medicine (2023) demonstrated substantial mean weight reductions over 48 weeks in adults with obesity among the highest figures reported for any pharmacological agent to date
Across 2,767 policies for 201 drug-indication pairs: Among the 168 drug-indication pairs where FDA labeling did not recommend prior corticosteroid use, 43.1% of policies still included corticosteroids in step therapy Plans were more likely to require corticosteroids when supported by pivotal trials or clinical guidelines
GHK itself has been identified in human biological contexts, but the evidence for GHK-Cu depends heavily on route, formulation, and study design